Genzyme GENZ

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. New operations chief at ImmunoGen

      Headlines

      Mon, 15 Sep 2014

      ImmunoGen ( IMGN -4% ) appoints Sandra E. Poole as SVP, Technical Operations reporting to CEO Daniel Junius. She joins the firm from Genzyme where she was SVP of biologics manufacturing. Post your comment!

    2. Positive interim results for Lemtrada

      Headlines

      Thu, 11 Sep 2014

      Genzyme (NYSE: SNY ) (NASDAQ: GCVRZ ) presents interim results from an extension study of Lemtrada ( alemtuzumab ) today at the European

    3. Genzyme looking for acquisitions to boost its position in MS

      Headlines

      Thu, 11 Sep 2014

      In an interview with Reuters , Genzyme 's (NYSE: SNY ) (NASDAQ: GCVRZ ) chief of its multiple sclerosis franchise Bill Sibold says his firm intends to be a leader

    4. Sanofi says MS drug Lemtrada shows sustained effect on disease

      Headlines

      Thu, 11 Sep 2014

      PARIS, Sept 11 (Reuters) - Sanofi rare disease unit Genzyme said its Lemtrada multiple sclerosis (MS) drug showed continued efficacy for four years in more than two thirds of patients and that no new safety risks had been identified in its latest studies.

    5. Sanofi aims to grow Genzyme unit with new drugs and acquisitions

      Headlines

      Thu, 11 Sep 2014

      PARIS, Sept 11 (Reuters) - Sanofi rare disease unit Genzyme hopes to become a leader in the multiple sclerosis (MS) field with the help of new products developed in-house but also through...

    6. ClearBridge Fund Prepared for Extended Rally

      Video Reports

      Fri, 11 Oct 2013

      continues. I think there is going to be a theme, which we've seen in our portfolio, where historically names like Genzyme , Chiron, Millennium, and ImClone have all been acquired, and what we're seeing today is Big Pharma continue to chase

      Genzyme found at 3:20

      a theme, which we've seen in our portfolio, where historically names like Genzyme , Chiron, Millennium, and ImClone have all been acquired, and what we're seeing today is Big Pharma continue to chase growth and do
    7. Invest With These Exemplary Management Teams

      Headlines

      Sun, 26 May 2013

      the Medley, Chattem, Merial, and Genzyme acquisitions all have generated returns ..... than four years. Additionally, the Genzyme acquisition shows how Sanofi avoided ..... value rights, or CVR, to appease Genzyme . Further, Viehbacher's decision

    8. Sanofi's 4Q and 2013 Guidance Match Our Projections but Fall Short of Consensus Expectations

      Commentary

      Thu, 7 Feb 2013

      quarterly results. The company's updated guidance on an improving pipeline along with steady growth from emerging markets, Genzyme products, consumer health, vaccines, and diabetes drugs increases our conviction behind our wide moat rating for the

    9. Sanofi Posts Solid 3Q Supported by Cost-Containment Efforts, but No Change to Valuation

      Commentary

      Thu, 25 Oct 2012

      growth continued to perform well, with particular strength from diabetes drug Lantus, which was up 18% year over year. Genzyme products and emerging markets also continued to post steady gains. However, generic competition to cardiovascular drug

    10. LabCorp Adds to its Reference Lab Network with Medtox Scientific

      Commentary

      Tue, 5 Jun 2012

      challenging macroeconomic conditions. LabCorp's purchases of Genzyme Genetics' diagnostics unit and Orchid Cellmark in 2010-11 ..... times sales for Medtox, and it paid 2.5 times sales for Genzyme 's diagnostics in 2010--considerably lower compared

    « Prev12345Next »
    Content Partners